Protoplast Regeneration from Normal and Bromodeoxyuridine-Resistant Sycamore Callus

Total Page:16

File Type:pdf, Size:1020Kb

Protoplast Regeneration from Normal and Bromodeoxyuridine-Resistant Sycamore Callus J. Cell Sci. i6, 445-463 0974) 445 Printed in Great Britain PROTOPLAST REGENERATION FROM NORMAL AND BROMODEOXYURIDINE-RESISTANT SYCAMORE CALLUS S. W. J. BRIGHT AND D. H. NORTHCOTE Department of Biochemistry, University of Cambridge, Cambridge, CBz iQW, England SUMMARY Protoplasts have been prepared from normal and mutant lines of sycamore callus, maize root and tobacco leaf. Fusion was rare in sodium nitrate solutions. A mutant tissue culture was selected for by its resistance to io/*g/ml bromodeoxyuridine. The mutant is sensitive to the Hypoxanthine-Aminopterin-Thymidine (HAT) selective medium but has normal thymidine transport and thymidine kinase activity. INTRODUCTION Tissue cultures of plant cells of many species can be induced under appropriate conditions to divide in an organized manner and to differentiate to whole plants (Steward, Mapes & Ammirato, 1969; Rao, Handro & Harada, 1973). It is now becoming experimentally possible to modify the genetic content of cultured cells and grow the tissues back to a plant. This could enable genetically useful traits, such as genes for disease resistance, to be introduced into a population of important plants where it could be propagated by conventional breeding techniques. This modification could range from the introduction of small amounts of foreign DNA to the introduction of organelles or the fusion of whole cells from genetically unrelated species. Plant cell hybridization would also be a very useful approach to studying problems of cellular organization and control. In one special case a hybrid plant has been produced from fused protoplasts and shown to be identical to the hybrid produced by conventional breeding techniques (Carlson, Smith & Dearing, 1972). We have been investigating: (1) conditions for the production of healthy protoplasts from a tissue culture of sycamore; (2) the effects of various reagents on the fusion of tobacco leaf, maize root and sycamore callus protoplasts; (3) conditions for the regeneration of walls by sycamore callus and for the resumption of cell division leading to callus formation; and (4) the production of mutant lines of tissue culture, which would be used in a system, developed for animal tissue culture cells, for selecting hybrid cells or protoplasts from a mixed population. The HAT selective system (Littlefield, 1964, 1966; Szybalski, Szybalska & Ragni, 1962) utilizes animal cells lacking in either thymidine kinase (EC. 2.7.1.21) or hypoxanthine guanosine phosphoribosyl transferase (EC. 2.4.2.8) for the selection of hybrid cells. These mutant cells are selected for by their resistance to the base 446 S. W. J. Bright and D. H. Northcote analogues bromodeoxyuridine or azaguanine (Littlefield, 1963; Kit, Dubbs, Piekarski & Hsu, 1963). Enzymic mutants of this sort would be extremely useful in plant protoplast fusion work as they would enable the selective growth of rare heterokaryons from a large number of homokaryons and unfused protoplasts. We have isolated a bromodeoxyuridine-resistant callus of sycamore and have also prepared protoplasts from it and studied their regeneration. MATERIALS AND METHODS Reagents Materials were Analytical Reagent grade or its equivalent. Aminopterin was obtained from Serva Ltd (Microbio Laboratories), thymidine phosphates from Sigma UK Ltd. [6-3H]- thymidine (2 mCi/ml) was obtained from the Radiochemical Centre (Amersham). Calcofluor white was a gift of the American Cyanamid Co. Tissue culture The tissue culture (S4) used in this study was derived from a hypocotyl explant of sycamore (Acer pseudoplatanus). The isolation and conditions for growth and differentiation of the S4 callus have been described (Wright & Northcote, 1972). The cells were grown in the PRL4 medium of Gamborg (1966) with the addition of 1 mg/1. of i-naphthyl-acetic acid and 2 % sucrose (growth medium). Agar (1 %) was used for the growth of solid calluses. Liquid suspensions of cells were grown in 500-ml conical flasks containing 100 ml of medium and an inoculum of 10-25 m' °f cells. The cells were shaken at 25 °C in the dark, and subcultured every 7-10 days. All cell cultures were maintained in a sterile condition. Media and glassware were autoclaved at 120 °C, at 103 kN m~* (15 lb in."1) for 30 min. The constituents of HAT medium (hypoxanthine io~* M, aminopterin io~6 M, thymidine io"4 M) and bromodeoxy- uridine were added to the solutions prior to autoclaving. Solutions containing high sorbitol concentrations or enzymes, were sterile-filtered by passage through a Millipore disk (045 /tm). All operations were performed on a sterile air bench. Packed cell volume was measured by centrifugation of liquid suspensions (10 ml) from replicate cultures at 50 g for 10 min in a sterile graduated centrifuge tube. The contents were then resuspended and replaced in the flask. Growth of solid tissues was measured by placing 3-5 replicate pieces of callus tissue of o-i±o-o5g on to 20 ml agar medium. The initial and later weights were measured and the mean percentage increase and standard error calculated. Microscopy Cells and protoplasts were viewed on a Zeiss Ultraphot II equipped with Nomarski optics and u.v. lamp. Petri dishes were viewed on a Union inverted microscope. Cell walls and remnants of cell wall material were detected by staining the protoplasts for 1 min with o-i % Calcofluor in growth medium and viewing under u.v. light. Protoplasts from sycamore callus Protoplasts were isolated from liquid suspension cultures of callus using a mixture of macerozyme (a pectinase) and Cellulase Onozuka SS (Unwin Ltd, Welwyn Garden City). The Onozuka was purified by passage through a Sephadex G-25 column in glass-distilled water (25 g/80 ml on 800 ml bed volume). The front running dark brown peak of material excluded from the gel was collected and freeze-dried (Hanke & Northcote, 1974). Cell suspension (20 ml) was mixed with an equal volume of 09 M sorbitol in growth medium. The cells were allowed to settle and the supernatant was drawn off down to 4 ml. To this was added 4 ml of 5 % cellulase and pectinase in 0-45 M sorbitol in growth medium. Regeneration of normal and mutant protoplasts 447 The pH of this mixture was in the range 4'8-5'4 and no adjustment was made. The cells were shaken gently on a reciprocal shaker for 4-12 h during which time protoplasts were released into the medium. The protoplasts were separated from the remaining cell clumps by a 43-/tm stainless steel mesh (R. Cadisch and Sons, Finchley), and then washed on a glass-fibre filter paper cone by dispensing 100 ml medium with 0-45 M sorbitol over them slowly with a Pasteur pipette. The last 10 ml of protoplast suspension in the filter funnel were poured off and then centrifuged at 45 g for 10 min to concentrate the protoplasts in 1-2 ml of medium. A sample was removed for counting in a haemocytometer and the rest of the protoplasts were embedded in agar medium by the method of Nagata & Takebe (1971). The final concentrations of components in the agar regeneration medium were agar o-6 %, sorbitol 0-45 M, calcium 5 mM, glucose and ribose C25 g/1. (Kao et al. 1973), zeatin 125 /tg/1., all in growth medium made up in Analar water. Leaf and root protoplasts Sterile maize (Zea mays var. Caldera 535) roots (15) each 1-3 cm long were taken from 4-day-old seedlings and chopped into 2-mm lengths before incubation in 8 ml purified cellulase (2-5 %) and pectinase (2-5 %) in 0-45 M sorbitol in growth medium. The mixture was gently shaken for 19 h or more and the protoplasts collected by passage through 63-/MT1 steel mesh and centrifugation. Mesophyll protoplasts were prepared by a modification of the method of Power & Frearson (IO73)- Mature leaves of Nicotiana Java or xanthi were surface-sterilized briefly in ethanol and then Milton solution (Richardson-Merrell Ltd., London) and washed in sterile water. The leaves were then allowed to wilt for 4 h before the lower epidermis was stripped from the leaf and the exposed mesophyll cells plasmolysed on 05 M sorbitol. The leaf pieces (0-5 g) were then laid on to 8 ml of purified cellulase (2^5 %) and pectinase (2-5 %). The flask was evacuated for 5 min to infiltrate the air spaces with enzyme solution. The leaf pieces were incubated for 12 h in enzyme solution before being strained through 43-/4111 steel mesh to separate the protoplasts. Fusion experiments were performed on freshly isolated protoplasts usually taken directly from the enzyme solution. Protoplast suspensions were spun at 11-50JJ to pellet them and were then resuspended in the test solution and spun again to bring about protoplast contacts. The pellet was then gently resuspended with a Pasteur pipette and a sample viewed for protoplast fusion and viability. Assay of thymidine kinase The assay is modified from Schwarz & Fites (1970). Suspension cells (4 days after sub- culture) were collected on 2 layers of muslin, and 5 g fresh weight were added to 5 ml of cold 04 M phosphate buffer (NaH,PO4. 2HaO, 24-3 g/1.; K2HPO4, 42-2 g/1.) pH 70. This was sonicated twice at 4 °C for 2-5 min to break the cells. The sonicate was centrifuged at 30000g for 30 min and the supernatant used as the enzyme preparation. The assay mixture consisted of enzyme extract 50 fi\; ATP 50 mM, MgCl,, 4 mM, 50 /i\; [6-'H]thymidine 0-19 mM, 325 /tCi/ml, 5 fi\; all in 0-2 M phosphate buffer pH 70. The assay mixture was incubated at 30 °C for 30 min and the reaction terminated by the addition of 03 ml cold methanol.
Recommended publications
  • Hybridoma Technology History of Hybridoma Technology
    Hybridoma Technology History of Hybridoma Technology What is hybridoma technology? Hybridoma technology is a well-established method to produce monoclonal antibodies (mAbs) specific to antigens of interest. Hybridoma cell lines are formed via fusion between a short-lived antibody-producing B cell and an immortal myeloma cell. Each hybridoma constitutively expresses a large amount of one specific mAb, and favored hybridoma cell lines can be cryopreserved for long-lasting mAb production. As a result, researchers usually prefer generating hybridomas over other mAb production methods in order to maintain a convenient, never-ending supply of important mAbs. Fig 1. Hybridoma technology Inventor: Georges Kohler and Cesar Milstein Hybridoma technology was discovered in 1975 by two scientists, Georges Kohler and Cesar Milstein. They wanted to create immortal hybrid cells by fusing normal B cells from immunized mice with their myeloma cells. For incidental reasons, they had all the requirements fulfilled and it worked in the first attempt. By cloning individual hybrid cells, they established the first hybridoma cell lines which can produce single type of antibody specific to the specific antigen. Their discovery is considered one of the greatest breakthroughs in the field of biotechnology. For the past decades, hybridomas have fueled the discovery and production of antibodies for a multitude of applications. By utilizing hybridoma technology, Sino Biological provides cost-effective mouse monoclonal antibody service, and we can deliver you purified antibodies in 60 days. Steps Involved in Hybridoma Technology Hybridoma technology is composed of several technical procedures, including antigen preparation, animal immunization, cell fusion, hybridoma screening and subcloning, as well as characterization and production of specific antibodies.
    [Show full text]
  • HAT Medium Supplement 50X, Liquid
    HAT Medium supplement 50X, Liquid w/ 680.5 mg/litre Hypoxanthine, 8.8 mg/litre Aminopterin and 193.8 mg/litre Thymidine in Phosphate Buffered Saline Sterile filtered Cell Culture Tested Product Code: TCL072 Product description: Directions for use: Monoclonal antibodies are produced by hybridoma 1. Aseptically transfer 10 ml of the 50X HAT medium technology in which a non-secreting myeloma cell line is supplement to 500ml of sterile medium. fused with an antibody-producing B-lymphocyte. After 2. Tightly cap the media bottle and mix gently to ensure fusion, the proportion of viable hybrids is low. Hence, proper mixing. selective media are required to favor the survival of Note: Do not mix vigorously as it may lead to hybrids at the expense of the parental cells. Hybrids are formation of foam. most frequently selected with the HAT system. 3. The final concentrations of hypoxanthine, aminopterin and thymidine in 500ml media will be HAT supplement contains Hypoxanthine, Aminopterin 100mM, 0.4mM and 16mM respectively. and Thymidine and is used for the preparation of selection medium for hybridoma. The myeloma cell is deficient in enzyme hypoxanthine-guanine phosphoribosyl transferase (HGPRT) or thymidine kinase (TK), and cannot survive in Quality Control: selection medium containing hypoxanthine, aminopterin Appearance and thymidine. Any unfused B-lymphocytes from the Colorless, clear solution spleen cannot survive in culture for more than a few days. pH It is essential for B-cell-myeloma hybrids to contain the 8.90 to 9.50 genetic information from both parent cells to enable them Cell Culture Test to survive in the HAT selection system.
    [Show full text]
  • Dynamics of Pyrimidine Deoxynucleoside Triphosphate
    Proc. Nati Acad. Sci. USA Vol. 80, pp. 1347-1351, March 1983 Cell Biology Dynamics of pyrimidine deoxynucleoside triphosphate pools in relationship to DNA synthesis in 3T6 mouse fibroblasts (nucleoside incorporation/compartmentation/amethopterin block) BjORN NICANDER AND PETER REICHARD Medical Nobel Institute, Department of Biochemistry I, Karolinska Institutet, Box 60400, S-104 01 Stockholm, Sweden Contributed by Peter A. Reichard, November 18, 1982 ABSTRACT The 3H-labeled nucleosides cytidine, deoxycyti- tivity into DNA to this value (1, 2). Such a procedure becomes dine, and thymidine are rapidly incorporated into DNA via dCTP imperative when one wishes to distinguish between effects of or dTTP pools. Between 30 and 60 minafter addition of tracer different manipulations-e. g., pharmacological interference- amounts ofa labeled nucleoside to the medium ofrapidly growing on precursor synthesis and DNA replication. Knowing the spe- 3T6 cells, dNTPpools attained a constant specific activity resulting cific activity of a dNTP under steady-state conditions may in from a steady-state equilibrium between incorporation of nucleo- addition permit determination of absolute rather than relative side, de novo synthesis, and linear incorporation of isotope into rates of DNA synthesis. DNA. Removal oflabeled deoxycytidine or thymidine depleted the The of dNTP pools ofisotope within a few minutes and incorporation into possibility compartmentation of dNTP pools poses DNA stopped. When de novo synthesis ofdTTP was blocked with additionalicomplications (3). Fractionation ofcells in nonaque- amethopterin, the intracellular dTTP pool rapidly reached the ous media led to -the suggestion of separate cytoplasmic and. specific activity of thymidine of' the medium and isotope-incor- nuclear dNTP pools in Chinese hamster ovary cells (4).
    [Show full text]
  • BIO 02 - Production of a Monoclonal Antibody Against SARS-Cov-2 and Determination of Viral Neutralization Capacity
    BIO_02 - Production of a monoclonal antibody against SARS-CoV-2 and determination of viral neutralization capacity Nathalie Bonatti Franco Almeida1*; Camila Amormino Corsini1; Priscilla Soares Filgueiras1; Daniel Alvim Pena de Miranda1; Lucélia Antunes Coutinho1; Patrícia Martins Parreiras1; Rafaella Fortini Grenfel e Queiroz1. 1Fiocruz/CPqRR. Introduction: The emergence of the new coronavirus (SARS-CoV-2) in Wuhan, China, caused a worldwide epidemic of respiratory disease (COVID-19). SARS-CoV-2 belongs to the genus Betacoronavirus. It has structural proteins that include the spike protein (S), the envelope protein (E), the membrane protein (M) and the nucleocapsid protein (N). Various reports were published relating the antibody responses generated against protein S, as it is the most exposed protein of SARS-CoV-2. Monoclonal antibodies (mAbs) have many applications in diagnosis, treatment and can contribute to study the COVID-19. Objective: Production of a monoclonal antibodies against SARS-CoV-2 spike protein and determination of the neutralization of SARS-CoV-2 infection. Methodology: 1. Mouse Immunizations.SARS-CoV-2 spike protein (GenBank: MN908947) was mixed with an equivalent volume of Vaccine Self-Assembling Immune Matrix (VacSIM) adjuvant and injected subcutaneously into BALB/c mice. 40 µg of protein was used in the first injection and 20 µg at 9, 23, 30, 36, 52, 58, 64 days after the first injection. Spike protein without adjuvant was injected intraperitoneally 3 days prior to removal of the mouse spleen and cell fusion. 2. Determination of antibody titer against Spike protein.To determine the antibody titer against the SARS-CoV-2 spike protein, at 6 days after each immunization, the serum from mice was tested by ELISA.
    [Show full text]
  • Hybridoma Technology & Monoclonal Antibody Production Definition
    Sanjib Kr Das B.Sc Hons. In ZOOLOGY 06.06.2020 Assistant Professor (WBES) SEM-IV Dept. of Zoology Paper- CC-10 Immunology Jhargram Raj College UNIT-4 Immunoglobulin Hybridoma Technology & Monoclonal Antibody Production Definition: Hybridoma A clone of hybrid cells formed by fusion of normal lymphocytes with myeloma cells. It retains the properties of the normal cell to produce antibodies or T-cell receptors but exhibits the immortal growth characteristic of myeloma cells. Hybridomas are used to produce monoclonal antibody (mAB). Monoclonal antibody Homogeneous preparation of antibody molecules, produced by a single clone of B lineage cells, often a hybridoma, all of which have the same antigenic specificity. (The term monoclonal refers to the fact that all of the cells in a given hybridoma culture are derived from the single clone of cells, and therefore carry the same DNA). A hybridoma is a fusion product of two cells. B-cell hybridomas are generated by artificially fusing antibody-producing, short-lived lymphocytes with long-lived tumor cells in order to generate long-lived daughter cells secreting large amounts of monoclonal antibodies. In 1975, Georges Köhler and Cesar Milstein figured out how to generate large quantities of antibodies derived from a single B-cell clone. By fusing a normal, activated, antibody-producing B cell with a myeloma cell (a cancerous plasma cell), they were able to generate a hybridoma that possessed the immortal growth properties of the myeloma cell parent and secreted the unique antibody produced by the B-cell parent. Over time, myeloma-cell partners were generated that had lost the ability to synthesize their own immunoglobulin, thus ensuring that the only antibodies secreted into the culture medium were those from the B-cell fusion partner.
    [Show full text]
  • Lecture on the Topic-Hybridoma Technology
    Course Code: ZOOL-2023; Course Title: Immunology Programme: B.Sc. Zoology (Hons.) Dr. Kundan Kishor Rajak Assistant Professor Deptt. of Zoology School of Life Sciences Mahatma Gandhi Central University Bihar • In hybridoma technology, monoclonal antibodies are made out side the body by hybrid cell cultures known as hybridomas. • Hybridomas are cells formed via fusion between a short-lived antibody-producing Plasma cell and an immortal myeloma cell (Cancer cell). Plasma cell Myeloma cell A naive B-lymphocyte Myeloma is a form of cancer immediately differentiate after that begins in the blood’s plasma encounters with an antigen into cells. memory B-cell and effector B- Plasma cell transformed into cells called Plasma cell. malignant cell known as Plasma cell produce secretory myeloma cell. antibody. Grow and spread It live for only a few days. uncontrollably. A single plasma cell can secrete Immortal in character. more than 2000 molecules of Myeloma cells are also produce antibody per second. secretory antibody but impaired. + = Plasma cell Myeloma cell Hybridoma cell In 1973, Jeriod Schwaber and Ed Cohen (from Liribida institute, University of Chicago) – First to produce hybridoma cell through fusion of human B-lymphocyte cells and myeloma cells . In 1975, Georges Kohler and Cesar Milstein (from Medical Research Council Laboratory, Cambridge, UK)- construct a continuous cell lines, which secrete monoclonal antibodies of a desired specificity. In 1984, Kohler and Milstein awarded Nobel Prize jointly with Niels Jerne in Physiology and Medicine. • The hybridoma technique involves the fusion of plasma cells (Effector B-Lymphocyte cells) harvested from spleen of mice, already immunized with immunogen, with a myeloma cell lines, which is capable of grow in animal cell culture medium.
    [Show full text]
  • MONOCLONAL ANTIBODY (Mab)
    MONOCLONAL ANTIBODY (mAb): Normal B lymphocytes and plasma cells do not survive for long or secrete significant quantities of antibodies in tissue culture. However there is a class of malignant B cell tumours called myelomas that can be propagated indefinitely in tissue culture and will proliferate rapidly, often secreting large quantities of immunoglobulins. Monoclonal antibodies are made by fusing antibody-secreting B cells with myeloma cells. These fused cells now become immortal (they will grow and divide indefinitely) and are called hybridoma. The hybridoma cells will secrete monoclonal antibodies. This technique was introduced by Kohler and Milstein in 1975 and were awarded Nobel Prize. © Sridhar Rao P.N (www.microrao.com) Procedure: Step 1: Immunization of Mice and Selection of Mouse Donors for Generation of Hybridoma Cells Mice are immunized with an antigen that is prepared for injection either by emulsifying the antigen with Freund's adjuvant or other adjuvants. In general, mice are immunized every 2-3 weeks. Step 2: Screening of Mice for Antibody Production After several weeks of immunization, blood samples are obtained from mice for measurement of serum antibodies. Serum antibody titer is determined with various techniques, such as enzyme-linked immunosorbent assay (ELISA). When the antibody titer is high enough, the mice are euthanized and their spleens removed for in vitro hybridoma cell production. Step3: Fusion of Myeloma Cells with Immune Spleen Cells Spleen cells from the immunized mouse are fused with the previously prepared myeloma cells. Fusion is accomplished by a technique called somatic cell hybridization. This is achieved by co-centrifuging freshly harvested spleen cells and myeloma cells in polyethylene glycol, a substance that causes cell membranes to fuse.
    [Show full text]
  • Transfer of the Gene for Thymidine Kinase to Thymidine Kinase-Deficient
    Proc. Natl. Acad. Sci. USA Vol. 74, No. 4, pp. 1590-1594, April 1977 Cell Biology Transfer of the gene for thymidine kinase to thymidine kinase-deficient human cells by purified herpes simplex viral DNA (transformation/gene expression/somatic cell genetics) SILVIA BACCHETTI* AND FRANK L. GRAHAM*t Departments of *Pathology and tBiology, McMaster University, Hamilton, Ontario, Canada L8S 4J9 Communicated by George Klein, January 6, 1977 ABSTRACT Transformation of human cells from a thymi- MATERIALS AND METHODS dine kinase (ATP:thymidine 5'-phosphotransferase, EC 2.7.1.75)negative to a thymidine kinase-positive phenotype has Cells and Virus. A line of TK- human cells, 143, derived been achieved by using pd DNA from herpes simplex virus from the murine sarcoma virus-transformed line R970-5 (5) by type 2. The specific activityo tLieDNA was in the range 0.5 to selection with BrdUrd at 60 ,g/ml (K. Huebner and C. Croce, 2.0 transformants per jig and the efficiency of gene transfer was was used as recipient for the HSV-2 up to 1 transformant per 105 recipient cells. Several transformed personal communication) lines able to grow continuously in medium selective for thymi- TK gene. (We. are grateful to K. Huebner and C. Croce for dine kinase-positive cells have been established. All of these providing both cell lines to us.) The lines were routinely grown lines express a thymidine kinase activity of viral origin but they in monolayer cultures in a minimal essential medium (a-MEM) differ from each other in the stability of enzyme expression.
    [Show full text]
  • PEG Fusions Routinely Produce One Viable Hybridoma from 105 Starting Cells
    222 / Chapter 7 PEG fusions routinely produce one viable hybridoma from 105 starting cells. This may be below the needed efficiency. One method that is gaining more widespread use is fusing cells by applying high- voltage electrical gradients across cell populations—a sequence of short bursts of electric current fuses adjacent membranes, increases membrane permeability, and yields hybrid cells. Electrofusion is accomplished in three steps: Pre-alignment of the cells (convergence and cell contact), membrane fusion, and post-alignment (rounding off the fused cells). This method has been applied successfully to hybridoma production with higher fusion efficiency, allowing production of more hybrid cells. In general, this has not been important for most fusions, because hybridoma production is normally lim- ited by the screening method rather than by the frequency of hybridoma production. As more rapid screening procedures are developed, this fusion method will become more important. In addition, as techniques are developed that allow the selection of the desired antibody-secreting cell before fusion, this and other high-efficiency methods will become increasingly valuable (see Protocol 21). PLATING STRATEGIES Several plating strategies have been used successfully to identify hybridomas that are secreting the appropriate monoclonal antibody. The strength of the immune response (titer) can be used as a guideline to predict the frequency of positive clones. A higher titer correlates well with the number of B cells that are producing circulating antibody, which also correlates with a greater number of positive clones resulting from the fusion. This suggests that cells from high-titer animals should be plated in an increased number of plates so that the cells will be at lower cell densities.
    [Show full text]
  • Absence of Hypoxanthine:Guanine Phosphoribosyltransferase Activity in Murine Dunn Osteosarcoma1
    [CANCER RESEARCH 43, 4098-4101, September 1983] Absence of Hypoxanthine:Guanine Phosphoribosyltransferase Activity in Murine Dunn Osteosarcoma1 Herbert T. Abelson2 and Carolyn Gorka Department of Pediatrics, Harvard Medical School, Division of Hematology-Oncology, Children's Hospital Medical Center, and Dana-Farber Cancer Institute, Boston Massachusetts 02115 ABSTRACT To examine salvage pathways more carefully with respect to osteosarcoma, we have studied the transplanted murine Dunn The transplantable murine Dunn osteosarcoma has no de osteosarcoma because it resembles human osteosarcoma in a tectable hypoxanthine:guanine phosphoribosyltransferase (EC number of characteristics, including metastasis to the lungs, 2.4.2.8) activity. This was established from the tumors directly surgical control of the transplanted primary being a requirement and from tissue culture cell lines derived from the tumor using a for cure, and response to adjuvant chemotherapy, including high- variety of assays: e.g., no [3H]hypoxanthine uptake into tumor dose MTX-LV (11). or tissue culture cells, no conversion of [3H]hypoxanthine to [3H]IMP by cell extracts from tumors or tissue culture cells, no growth of tissue culture cells in hypoxanthine:aminopterin: MATERIALS AND METHODS thymidine medium, and normal growth of these cells in 10 UM 6- Animals. C3H/HeJ mice were obtained from The Jackson Laboratory, mercaptopurine. Ten human osteosarcomas have been assayed, Bar Harbor, Maine, and were fed Charles River Rat, Mouse, and Hamster and two have no apparent hypoxanthine:guanine phosphoribo Formula and water ad libitum. Three- to 6-month-old animals were used syltransferase enzyme activity. After high-dose methotrexate for these experiments. treatment in vivo, murine tumors could be selectively killed and Radiolabeled Compounds and Drugs.
    [Show full text]
  • Thymidylate Synthetase Overproduction in 5-Fluorodeoxyuridine-Resistant Mouse Fibroblasts CINDY ROSSANA, LAKSHMI GOLLAKOTA RAO, and LEE F
    MOLECULAR AND CELLULAR BIOLOGY, Sept. 1982, p. 1118-1125 Vol. 2, No. 9 0270-7306/82/091118-08$02.00/0 Copyright 0 1982, American Society for Microbiology Thymidylate Synthetase Overproduction in 5-Fluorodeoxyuridine-Resistant Mouse Fibroblasts CINDY ROSSANA, LAKSHMI GOLLAKOTA RAO, AND LEE F. JOHNSON* Department ofBiochemistry, The Ohio State University, Columbus, Ohio 43210 Received 9 February 1982/Accepted 29 April 1982 We describe the isolation and characterization of a series of 5-fluorodeoxyuri- dine (FdUrd)-resistant mouse 3T6 cell lines that overproduce thymidylate synthe- tase (TS) by up to 50-fold compared with the parental cells. The resistant cells were selected by growing 3T6 cells or a methotrexate-resistant 3T6 cell line (M50L3, isolated previously in our laboratory) in gradua$ increasing concentra- tions of FdUrd. Uridine and cytidine were included in the culture medium to reduce toxicity from metabolic products of FdUrd. Cells that were resistant to the drug by virtue of loss of thymidine kinase activity were eliminated by selection in medium containing hypoxanthine, methotrexate, and thymidine. M5OL3 cells were found to adapt to FdUrd more readily than 3T6 cells. A number of clones were isolated that were able to grow in the presence of 3 ,uM (M50L3 derived) or 0.3 ,uM (3T6 derived) FdUrd. Several were found to overproduce TS by 10 to 50- fold compared with normal 3T6 cells. All were found to have thymidine kinase activity, although the enzyme level was significantly reduced in some clones. The overproduced TS was inactivated by 5-fluorodeoxyuridylic acid at the same concentration as the enzyme from 3T6 cells.
    [Show full text]
  • Human-Human Hybridomas Producing Monoclonal Antibodies Of
    Proc. Natl. Acad. Sci. USA Vol. 77, No. 9, pp. 5429-5431, September 1980 Immunology Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity (somatic human cell hybrids/anti-hapten antibodies) LENNART OLSSON AND HENRY S. KAPLAN Cancer Biology Research Laboratory, Stanford University School of Medicine, Stanford, California 94305 Contributed by Henry S. Kaplan, June 30, 1980 ABSTRACT We report the establishment of human-human 1640/15% FCS/5 ,g of 8-AG per ml. The concentration of hybridomas producing monoclonal antibody of predefined 8-AG was then gradually increased to 20,ug/ml, and viable cells antigenic specificity. The U-266 human myeloma cell line was were cloned in RPMI 1640/15% FCS/20,ug of 8-AG per ml. incubated in the presence of 8-azaguanine, and a rapidly Cultures of the fastest-growing 8-AG-resistant clone were ex- growing, 8-azaguanine-resistant, hypoxanthine/amethop- that were HAT sensitive. This terin/thymidine (HAT) medium-sensitive mutant line, U- panded, after verifying they 266ARI, was selected. These cells were fused with lymphoid mutant cell line, U-266AR1, is routinely maintained in RPMI cells from uninvolved spleens removed at staging laparotomy 1640/15% FCS/5 ,ug of 8-AG per ml. from patients with untreated Hodgkin's disease who had been Human Spleen Lymphoid Cells. Fresh spleen specimens previously sensitized to the chemical allergen 2,4-dinitrochlo- were obtained from untreated patients with Hodgkin's disease robenzene. Hybrid cell cultures growing in HAT medium were undergoing staging laparotomy with splenectomy (9). Only screened for IgG production. Positive cultures were selected and spleens that, on pathological examination, appeared devoid of their supernatants were tested in a solid-phase radioimmuno- involvement by Hodgkin's disease were used.
    [Show full text]